Drug Research
Fusion Antibodies and Queens University Belfast Receive Invest Northern Ireland Grant to Boost Research and Development for COVID-19 Antibodies
Fusion Antibodies, pre-clinical antibody discovery, engineering and supply experts, and Queen’s University Belfast, leader in innovation and impact, have been awarded a £453,000 grant from...
Drug Research
U.S. FDA confirms Pfizer COVID vaccine safe & effective
The FDA 53-page briefing document gives a green signal to Pfizer-BioNTech COVID-19 vaccine. A US roll-out of the vaccine is expected post-approval from an outside...
Drug Research
UK Begins The Biggest Immunization Program In Its History
The UK has begun immunizing citizens against Coronavirus.
Population above 80, the most vulnerable and the front line health care workers to be administered...
Drug Research
Russia Begins Sputnik V Coronavirus Vaccine Distribution
Sputnik V has been rolled out in Moscow and will be subsequently distributed across other Russian cities.
One needs to see if this will...
Drug Research
KaliVir Immunotherapeutics, Astellas ink research agreement to develop and commercialise VET2-L2 novel oncolytic virus
KaliVir Immunotherapeutics LLC and Astellas Pharma Inc announced that they entered into a worldwide licensing agreement for the research, development, and commercialization of VET2-L2, an...
Drug Research
Catalent to Invest $10 Million to Expand High Potency Containment Capabilities for Micronization
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced...
Drug Research
Lilly and UnitedHealth Group partner on pragmatic study of neutralizing antibody bamlanivimab for COVID-19
Eli Lilly and Company and UnitedHealth Group announced a partnership to conduct a pragmatic study of bamlanivimab (LY-CoV555) in high-risk, COVID-19 infected individuals.
Bamlanivimab recently received...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.